Basic characteristics of patients
renal impairment, anemia, heart and kidney failure
MULTIPLE MYELOMA, RENAL IMPAIRMENT, ANEMIA, TRISOMY, ONCOLOGY
According to the inclusion criteria, we enrolled 42 patients. The patients who received at least two‐cycle therapy were assessed. Following patients were excluded: one patient died during the first cycle of chemotherapy because of heart and kidney failure caused by multiple myeloma, three patients switched to cheaper regimens for economic reasons after one cycle, and two patients had not finished the first or second cycle, respectively. As patients who received at least two cycles were analyzed in this study, these six patients were excluded. Therefore, a total of 36 patients from three centers in China were assessed in this study. Among them, 19 patients were included in the ICd group and 17 in the Id group. The median follow‐up duration was 13.5 months (range: 2–24 months). The median age was 75 years (range: 60–87 years); 52.8% of patients were ≥ 75 years old and 41.7% of the patients were men. Furthermore, 75.0% and 61.1% of patients had anemia and renal impairment in various degrees, respectively. The ISS III stage was identified in 55.6% of the patients. The detailed characteristics of the patients at baseline are presented in Table Baseline clinical characteristics of the patientsCardiovascular/pulmonaryComorbidity‐
Abbreviations: DS, Durie‐Salmon; eCCr, estimated creatinine clearance rate; ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin; ISS, International Staging System; R‐ISS, Revised International Staging System.<75 years.Includes Trisomy, Includes 